New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
08:04 EDTLGNDLigand says LGD-6972 well-tolerated in Phase 1 study
Ligand Pharmaceuticals announced data from a Phase 1 clinical trial with LGD-6972 that demonstrate favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus, and also demonstrate a robust response on fasting plasma glucose after a single dose. LGD-6972 is Ligandís novel glucagon receptor antagonist and these first-in-human data were presented at the American Diabetes Associationís 74th Scientific Sessions meeting underway in San Francisco. Highlights of the single-ascending dose trial involving a total of 56 subjects include: LGD-6972 was well-tolerated; there were no clinically significant or dose-dependent changes in hematology, clinical chemistry, urinalysis, ECG or vital signs, and no serious adverse events. LGD-6972 was well-absorbed after oral administration; peak plasma concentrations were reached approximately 5 to 8 hours post dose with a long elimination half-life of approximately 50 hours, supporting once-daily dosing. After a single dose, LGD-6972 reduced fasting plasma glucose in normal healthy volunteers and in subjects with type 2 diabetes. Fasting plasma glucose was reduced by 57 mg/dL in subjects with type 2 diabetes, suggesting a robust response in this acute study.
News For LGND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 8, 2014
11:11 EDTLGNDLigand Q3 pre-announcement unlikely to rally stock, says Cantor
Cantor said its views Ligand's pre-announcement of better than expected Q3 results as no more than "a shuffling of the deck chairs" since the company did not also raise its view for the fiscal year. The firm said it does not expect upward momentum for the stock in the near-term and maintains its Hold rating on the shares.
08:34 EDTLGNDLigand maintains FY14 adjusted EPS $1.50-$1.55, consensus $1.55
Subscribe for More Information
08:33 EDTLGNDLigand sees Q4 revenue $22.5M-$24.5M, consensus $23.54M
08:33 EDTLGNDLigand sees Q3 adjusted EPS 33c-37c, consensus 32c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use